Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Issue 1 (2004)

• Record Type: Journal Article
• Authors: Petrkova, Jana; Szotkowska, Jaroslava; Hermanova, Zuzana; Lukl, Jan; Petrek, Martin
• Is Part Of: Mediators of inflammation. Volume 13:Issue 1(2004)
• Page Start: 39
• Page End: 43
• Publication Date: 2004
• Subjects: Monocyte chemoattractant protein-1 -- CC chemokine ligand 2 -- Atherosclerosis -- Artheritis obliterans -- Risk factors -- Low-density lipoprotein; Inflammation -- Mediators -- Periodicals; Biological response modifiers -- Periodicals; Inflammation (Pathologie) -- Médiateurs; Immunomodulateurs; Biological response modifiers; Inflammation -- Mediators; Immunology; Autacoids; Immunologic Factors; Cell Adhesion Molecules; Cell Communication; Cytokines; Inflammation; Periodicals; Electronic journals; 616.0473
• DOI: 10.1080/09629350410001664752
• Languages: English
• ISSNs: 0962-9351

Abstract

Abstract : Background: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD. Methods: Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation( p < 0.05 ) . Results: MCP-1 (pg/ml) was increased in patients compared with in controls (mean±standard error of the mean: PAD group, 748±60; control group, 459±27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein. Conclusion: Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.